About Tanox
Tanox is a company based in Houston (United States) founded in 1986, and was acquired by Genentech in November 2006. Drugs for immune system diseases are developed and tested.
Company details
Tanox, acquired by Genentech, was the co-developer of the Asthma drug Xolair. Tanox was also focused on developing TNX-355, an experimental AIDS drug that had advanced to a large-scale human test, and also tested a compound for treating age-related macular degeneration, a blinding eye disease.nbsp;Xolair received FDA approval in June 2003. Xolair posted 107 million in U.S. sales in 2006, and Genentech paid a royalty of 8 to 12 percent to Tanox.nbsp;
Investors in Tanox
Tanox has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Genentech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for Tanox
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Tanox
3 dated milestones of Tanox across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Tanox is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Genentech.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tanox
Tanox was founded in 1986.
Tanox is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Tanox, acquired by Genentech, was the co-developer of the Asthma drug Xolair. Tanox was also focused on developing TNX-355, an experimental AIDS drug that had advanced to a large-scale human test, and also tested a compound for treating age-related macular degeneration, a blinding eye disease.nbsp;Xolair received FDA approval in June 2003. Xolair posted 107 million in U.S. sales in 2006, and Genentech paid a royalty of 8 to 12 percent to Tanox.nbsp;.
Tanox has 1 investor. Key investors include Genentech.
Yes. Tanox was acquired by Genentech in November 2006.